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Background: Remogliflozin etabonate (RE) is the prodrug of remogliflozin, a selective inhibitor of the renal
sodium-dependent glucose transporter 2 (SGLT2), which could increase urine glucose excretion (UGE) and lower
plasma glucose in humans.
Methods: This double-blind, randomized, placebo-controlled, single-dose, dose-escalation, crossover study is the
first human trial designed to evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RE. All
subjects received single oral doses of either RE or placebo separated by approximately 2 week intervals. In Part A,
10 healthy subjects participated in 5 dosing periods where they received RE (20 mg, 50 mg, 150 mg, 500 mg, or
1000 mg) or placebo (4:1 active to placebo ratio per treatment period). In Part B, 6 subjects with type 2 diabetes
mellitus (T2DM) participated in 3 dose periods where they received RE (50 mg and 500 mg) or placebo
(2:1 active to placebo per treatment period). The study protocol was registered with the NIH clinical trials data base
with identifier NCT01571661.
Results: RE was generally well-tolerated; there were no serious adverse events. In both populations, RE was rapidly
absorbed and converted to remogliflozin (time to maximum plasma concentration [Cmax;Tmax] approximately 1 h).
Generally, exposure to remogliflozin was proportional to the administered dose. RE was rapidly eliminated (mean
T½ of ~25 min; mean plasma T½ for remogliflozin was 120 min) and was independent of dose. All subjects showed
dose-dependent increases in 24-hour UGE, which plateaued at approximately 200 to 250 mmol glucose with RE
doses ≥150 mg. In T2DM subjects, increased plasma glucose following OGTT was attenuated by RE in a
drug-dependent fashion, but there were no clear trends in plasma insulin. There were no apparent effects of
treatment on plasma or urine electrolytes.
Conclusions: The results support progression of RE as a potential treatment for T2DM.
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Type 2 diabetes mellitus (T2DM) is characterized by
abnormalities of glucose and lipid homeostasis, which
drive secondary micro- and macrovascular complications.
Clinical evidence indicates that maintaining glycemic
control and reducing postprandial glucose excursions
can lower the risk of diabetic complications, e.g. reduce the
risk of myocardial infarction, renal disease and retinopathy
[1,2]. Despite the availability of multiple classes and
combinations of antidiabetic agents, the clinical manage-
ment of T2DM remains challenging, with the majority of
patients failing to achieve and maintain target glycemic
levels in practice [3]. There is a continued need for
novel therapeutic approaches, particularly those with
complementary modes of action that will enable further
improvement of glycemic control.
Glucose homeostasis is a complex process controlled
by gastrointestinal absorption, tissue utilization, hepatic/
renal gluconeogenesis and renal filtration/reabsorption/
excretion. Under normal physiological conditions when
the glomerular filtrate reaches the proximal tubule,
glucose is primarily reabsorbed through the active sodium-
dependent glucose transporter 2 (SGLT2) located on the
apical or luminal membrane of the epithelial cell in the
S1 segment [4-6].
SGLT1 is a high-affinity, low-capacity glucose/galactose
co-transporter primarily expressed in the intestine and
in the kidney [7,8]. In contrast, SGLT2 is a low-affinity,
high-capacity glucose transporter selectively expressed
in the kidney. Together, SGLT1 and SGLT2 are responsible
for the active reabsorption of glucose across the renal
luminal membrane [9,10]. Once reabsorbed by the
renal epithelial cell, glucose is transported to the blood
by facilitated diffusion via the sodium-independent glu-
cose transporter 2 (GLUT-2). The uptake of glucose in the
proximal tubules by SGLT1 and SGLT2 is highly efficient,
resulting in complete reabsorption of glucose. In humans,
genetic alterations in SGLT2 increase renal glucose excre-
tion (up to 200 g/day) with no apparent adverse effects on
renal function or carbohydrate metabolism [11].
SGLT2 is currently the focus of interest as a potential
therapeutic target for reducing hyperglycemia in T2DM,
and several selective SGLT2 inhibitors have been devel-
oped [12-16]. In diabetic animal models, pharmacological
inhibition of SGLT2 leads to glucosuria, and improvement
of plasma glucose levels, followed by a reduction of insulin
resistance [17-19].
SGLT2 inhibitors have the potential to offer distinct
advantages over currently available diabetic treatments.
Because SGLT2 inhibitors work by an insulin-independent
mechanism, this class of compounds may be of benefit as
adjunctive therapy in patients whose pancreatic function is
diminished or in patients who have insulin resistance. Thus,
treatment with SGLT2 inhibitors may be appropriate in allstages of T2DM, provided the patient still has adequate
renal function to deliver the drug to the site of action in the
kidney. Another advantage is that SGLT2 inhibitors cause
calorie wasting by loss of glucose in the urine, thus offering
the potential for promoting weight loss, whereas some
other anti-diabetic treatments such as sulfonylureas and
insulin promote weight gain.
Remogliflozin etabonate is the ester prodrug of
remogliflozin [20], which is the active entity that select-
ively inhibits SGLT2. Remogliflozin undergoes further
transformation to GSK279782, an active metabolite. The
structures of remogliflozin etabonate, remogliflozin and
GSK279782 are presented in Figure 1.
Remogliflozin etabonate causes a concentration-
dependent increase in urinary glucose excretion in
mice and rats [20,21]. Unlike earlier SGLT inhibitors,
such as phlorizin and T-1095, remogliflozin displays a
high level of selectivity for SGLT2 over SGLT1 [22].
This single-dose evaluation was the first study to be
conducted with remogliflozin etabonate in humans
and was designed to provide safety, tolerability, PK and
pharmacodynamic information.
Methods
This single center study was conducted at Profil Institute
for Clinical Research (Chula Vista, CA, USA) and was
conducted in accordance with Good Clinical Practice
and the principles of the Declaration of Helsinki. The
study protocol and subject information were reviewed
and approved by Biomedical Research Institute of America
investigational reviewer board (San Diego, CA, USA)
and all subjects provided written, informed consent
prior to start of study-related procedures.
Subjects
Ten healthy male and female subjects followed by a
separate group of 6 subjects with T2DM were enrolled
in this study. Enrollment of women was restricted to
those who were postmenopausal or surgically sterile. All
subjects gave written informed consent prior to partici-
pation in any study-related procedures. Healthy subjects
were required to be 18–55 years of age, and have a body
mass index (BMI) of 19.0 to 30.0 kg/m2 inclusive.
Subjects with T2DM were required to be 30–60 years of
age, have a BMI of 22–35 kg/m2, to be healthy other
than having been diagnosed with T2DM at least 6 months
prior to entry in the study, and to have been maintained on
a stable treatment regimen for at least 3 months. Diabetic
subjects were required to have hemoglobin A1c (HbA1c)
≤10% and fasting plasma glucose <280 mg/dL at screening.
Participants with diabetes were required to be on a stable
treatment regimen using a single oral antidiabetic agent
(either sulfonylureas, rosiglitazone, metformin or acarbose)











































Figure 1 Structures of remogliflozin etabonate, remogliflozin, and GSK279782. Structures of (A) remogliflozin etabonate, (B) remogliflozin
and (C) GSK279782).
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their diabetes medications for up to 72 h during each
treatment period. Subjects were excluded if they had been
taking diuretics, corticosteroids or other medications that
might result in electrolyte depletion; had required insulin
during the last 3 months; had significant renal disease; or
if their participation would have resulted in donation of
blood in excess of 550 mL within an 8-week period.
Study design
This double-blind, randomized, placebo-controlled,
single escalating-dose crossover study was conducted
in two parts: Part A consisted of a randomized, dose-
escalation in healthy subjects; Part B was of similar design,
but conducted in subjects with T2DM and included an
evaluation of pharmacodynamics using a 50 g oral glucose
tolerance test (OGTT).
Part A
Ten healthy subjects were evaluated in 5 study sessions,
each separated by approximately 2 weeks. At each
study session, subjects received either an oral dose of
remogliflozin etabonate or placebo after an overnight
fast. Remogliflozin etabonate doses were 20 mg, 50 mg,
150 mg, 500 mg and 1000 mg. Over the course of par-
ticipation in the study, each subject received 4 of the 5
active remogliflozin etabonate doses and 1 dose of pla-
cebo (4:1 active to placebo ratio per treatment period).
The available safety and PK results from each dosing
period were evaluated before proceeding to the next
dose level.Part B
Six subjects with T2DM received two doses of remogliflozin
etabonate and a placebo dose, in a randomized, dose escal-
ating, crossover design, along with an oral glucose load on
three study sessions separated by 7–14 days. Full PK and
safety profiles were measured on Day 1 of each dosing
period. The doses selected for this portion of the study,
50 mg and 500 mg, were based on data obtained in Part A.
In each dosing period, subjects were assigned to active vs
placebo in a 2:1 ratio.
All subjects were admitted to the unit two nights prior
to receiving study drug to establish baseline safety
parameters and fluid intake levels over a 36 h period.
Subjects remained in the unit for at least 24 h after
doses were administered for monitoring of clinical la-
boratory parameters exploratory biomarkers, vital signs,
ECGs and adverse events. While confined to the clinical
research unit, all subjects received meals standardized
with respect to calories, fat, protein, carbohydrate, and
sodium content; however, detailed dietary information
was not captured in this study. In Part A, subjects were
dosed following an overnight fast; lunch and dinner were
provided at 4 and 10 h after dosing, respectively.
Fifteen minutes after dosing in each treatment period in
Part B, a fasting OGTT was performed using 50 g glu-
cose (administered as 50 g Glucola™). A 50 g glucose
load was chosen since the OGTT was being performed
in subjects already known to have diabetes. The glucose
drink was consumed by subjects within approximately
5 minutes. Blood samples for the measurement of glucose,
insulin, and intact glucagon-like peptide 1 (GLP-1) were
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vided that there were no safety or tolerability concerns,
subjects were released from the clinic on day 2 of each
treatment period until their return for the next treatment
or follow-up period. Each subject was involved in the study
for approximately 8 weeks (from screening to follow-up).
Pharmacokinetic assessments
Blood collections and analysis
On each dosing day, a series of 2.0 mL blood samples
were collected at pre-dose and 10, 20, 30 and 45 min, and
1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 h post-dose for
the determination of remogliflozin etabonate, remogliflozin
and GSK279782 in plasma by using high-performance
liquid chromatography with tandem mass spectrometry
(MS/MS) as described [23].
Pharmacokinetic calculations
Non-compartmental PK analysis of plasma concentra-
tion–time data was performed using WinNonlin Version
4.1 (Pharsight Corporation, Mountainview, CA, USA).
The Cmax and Tmax were obtained directly from the data.
Areas under the plasma concentration–time curves from
time zero to the last quantifiable time point (AUC[0–last])
and extrapolated to infinity (AUC[0–∞]) were calculated
using the log-linear trapezoidal method. The terminal
plasma elimination rate-constant (λz) was estimated
from log-linear regression analysis of the terminal phase
of the plasma concentration–time curve, and the T½ was
calculated as T½ = ln2/λz. Ratios of AUC(0–∞) remogliflozin
to AUC(0–last) remogliflozin etabonate were calculated
including molecular weight corrections.
Pharmacodynamic assessments
Plasma pharmacodynamics
Blood samples for glucose were taken at 0 (pre-dose),
and 1, 2, 4, 8 and 12 h after dosing in each treatment
period (Part A). For Part B, blood samples for glucose,
insulin and GLP-1 were taken at check-in on day -2, and
at 0 h (pre-dose), and 0.5, 1, 1.5, 2, 4 h (prior to lunch),
4.5, 5, 6, 8, 10, 12 and 24 h after dosing on day 1 of each
treatment period.
Glucose and insulin sample handling For glucose,
plasma was analyzed using a YSI 2300 Glucose Analyzer
(Yellow Springs International Life Sciences, Yellow Springs,
OH, USA). For insulin, plasma was rapidly prepared and
frozen at -70°C until analyzed by LabCorp (San Diego,
CA, USA) using a chemiluminescent immunometric assay
method (Siemen’s Immulite 2000 analyzer with Immulite
Insulin Kit L2KIN2).
GLP-1 sample handling For assay of intact GLP-1,
blood was collected into a chilled EDTA tube and proteaseinhibitors (DPP4 inhibitor obtained from EMD Millipore,
St. Charles, MO) were immediately added. Samples were
then spun down and plasma split into two separate tubes
and frozen at -70°C until analyzed by Pathway Diagnostics
(Malibu, CA, USA) by ELISA (kit # EGLP-35 K, EMD
Millipore). The lowest level of intact GLP-1 this assay
can detect is 2 pM (with a minimum plasma sample
size of 0.4 mL).Urine pharmacodynamics
Sample collection
Urine samples were collected at pre-dose, and over a
series of intervals (0–2, 2–4, 4–6, 6–8, 8–12 and 12–24 h
post-dose) for the analysis of creatinine, glucose and
electrolytes (Na, K and Cl). All fluid intake was recorded,
as well as urine volume, over the 24 hours before and
after dosing in each treatment period. Urine was tested
for protein on the first morning void of day -1 and 24 h
after dosing.Calculations
Creatinine clearance (CLCR) was calculated as the amount
of creatinine excreted in 24 h (Ae0–24 h) divided by the
mean of the pre-dose and 24-h post-dose plasma creatin-
ine levels. The percentage of filtered glucose excreted in
the urine for each individual time period was calculated as
the amount of glucose excreted during that time period
divided by (CLCR × PG × time interval length), where
CLCR is the creatinine clearance for the time interval,
PG is the plasma glucose concentration closest to the
midpoint of the time interval, and the time interval is
the period (min) of urine collection (CLCR × PG rep-
resents the glucose filtered load). For the 24-h period,
the percentage of filtered glucose excreted was calcu-
lated as the amount of glucose excreted over 24 h di-
vided by the sum over the individual time intervals of
(CLCR × PG × time interval length).Statistical analysis
Safety and pharmacodynamic data were summarized
using descriptive statistics. This was a small exploratory
study and no formal hypothesis-testing was conducted.
Dose proportionality with respect to Cmax, and AUC was
assessed using the power model y = α doseβ, where y =Cmax
or AUC, and α denotes a random subject effect. The
exponent β in the power model will be estimated by
regressing the loge-transformed PK parameters on loge
dose, i.e. ln(PK parameter) = ln(α) + β * ln(dose). Dose
proportionality implied that β = 1 and was assessed by
estimating β and its corresponding 90% confidence
interval. The power model was fitted by restricted
maximum likelihood using SAS Proc Mixed.
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Subject demographics
In Part A, 10 subjects (8 males, 2 females, mean age of
39 years, mean BMI of 24.5 mg/kg2, and mean baseline
fasting plasma glucose 4.7 mmol/L [range 4.2 to
5.1 mmol/L, SD 0.29 mmol/L]) were randomized; 9
completed the study (1 subject participated in all the
study visits but did not return for the follow up visit).
In Part B, 6 T2DM subjects (2 males, 4 females, mean
age of 53 years, mean BMI of 30.5 mg/kg2, and mean
baseline fasting plasma glucose 8.9 mmol/L [range 5.81
to 12.1 mmol/L, SD 2.47 mmol/L]) were randomized
and all completed the dosing period.
Safety and tolerability
Remogliflozin etabonate was generally well-tolerated by all
subjects. There were no obvious patterns suggesting an
effect of remogliflozin etabonate on clinical laboratory
results, urine electrolytes, vital signs or ECGs. There were
no deaths, serious adverse events or adverse events (AEs)
leading to withdrawal. The most frequently reported AE
was headache. AEs are summarized in Table 1.
Urine beta-2 microglobulin levels, an exploratory bio-
marker that was measured as a potential early indicatorTable 1 Summary of adverse events
Placebo 20 mg
Healthy Subjects n = 10 n = 8
n (%) n (%)
At least one adverse event 4 (40) 2 (25)
Adverse events reported by >1 subject in total
Headache 1 (10) 1 (13)
Blood creatine phosphokinase increased 1 (10) 0
Drug-related adverse events
Headache 1 (10) 1 (13)
Dizziness 0 0
Diarrhea 0 1 (13)
Hot flush 0 0
T2DM subjects n = 6
n (%)
At least one adverse event 3 (50)
Adverse events reported by >1 subject in total





Pain in extremity 0
n = number of subjects reporting event.
% = percentage of subjects reporting event.of renal toxicity, were within the normal range at both
baseline and after treatment for all subjects except for
two subjects with diabetes.
One of these subjects had normal beta-2 microglobulin
values at 1 and 4 days after dosing with 500 mg
remogliflozin etabonate. However, 11 days after dosing, this
subject returned to the clinic for the Day -2 visit of the 3rd
treatment period. At this time, the subject’s beta-2
microglobulin levels were elevated to 2.5 μg/mL. The values
returned to normal (<0.3 μg/mL) within 2 days. The inves-
tigator attributed the elevated pre-placebo levels to other
concomitant disease. A second subject, however, did have
what was considered by the investigator to be a drug-
related elevation of beta-2 microglobulin of 1.62 μg/mL on
day 1 after dosing with 500 mg remogliflozin etabonate.
The value returned to normal levels within 4 days. No
associated changes in serum creatinine and urea or
urine microalbumin were observed.
Pharmacokinetics
Healthy subjects
PK parameters are summarized in Table 2 (remogliflozin
etabonate), and Table 3 (remogliflozin and GSK279782).
Remogliflozin etabonate was rapidly absorbed andRemogliflozin etabonate dose
50 mg 150 mg 500 mg 1000 mg Total
n = 8 n = 8 n = 8 n = 8 n = 10
n (%) n (%) n (%) n (%) n (%)
3 (38) 1 (13) 3 (38) 1 (13) 8 (80)
1 (13) 0 2 (25) 1 (13) 4 (40)
0 0 1 (13) 0 2 (20)
1 (13) 0 0 1 (13) 3 (30)
0 0 0 1 (13) 1 (10)
0 0 0 0 1 (10)
0 0 0 1 (13) 1 (10)
n = 6 n = 6 n = 6
n (%) n (%) n (%)
1 (17) 2 (33) 4 (67)
1 (17) 0 2 (33)
0 2 (33) 2 (33)
0 1 (17) 1 (17)
0 1 (17) 1 (17)
0 1 (17) 1 (17)
Table 2 Summary of plasma remoglifozin etabonate pharmacokinetic parameters in healthy subjectsa,b
Remogliflozin etabonate dose 20 mg 50 mg 150 mg 500 mg 1000 mg
AUC(0–∞) (ng•h/mL) NQ
c 3.70 (46)d 9.77 (48)d 36.8 (67)e 126 (44)f
AUC(0–t) (ng.h/mL) 1.61 (67)
g 3.56 (56) 9.51 (42) 35.4 (62) 107 (53)
Cmax (ng/mL) 1.89 (78) 4.98 (61) 17.6 (48) 41.6 (81) 144 (59)
Tmax (h) 0.625 0.625 0.515 1.25 0.625
0.33-2.03 0.17-1.50 0.17-1.50 0.33-2.50 0.33-2.50
T½ (h) NQ
c 0.353 (56)d 0.256 (35)d 0.263e (27) 0.707f (56)
a. Geometric mean and CV% except for Tmax (median and range).
b. n = 8 unless otherwise specified.
c. NQ, not quantifiable because concentrations at later time points were below the limit of quantification.
d. n = 6.
e. n = 4.
f. n = 7.
g. n = 5.
Kapur et al. BMC Pharmacology and Toxicology 2013, 14:26 Page 6 of 11
http://www.biomedcentral.com/2050-6511/14/1/26extensively hydrolyzed to the active entity in all dose
groups. The median Tmax estimates for the prodrug
ranged from 0.52 to 1.25 h and median T½ estimates
ranged from 0.26 to 0.71 h. The concentration–time
profiles are shown for the 50 mg dose in Figure 2
illustrating low circulating plasma concentrations of
prodrug relative to active entity.
Remogliflozin appeared in plasma at relatively high
concentrations within 10 min of remogliflozin etabonate
dosing. Mean remogliflozin Cmax of the active entity
occurred within 1.5 h of prodrug dosing and was eliminated
from plasma more slowly than prodrug. The mean T½
estimates ranged from 1.38 to 2.86 h. The AUC(0-∞) ratios
of remogliflozin to prodrug (or AUC(0-t) when AUC(0-∞)
not available for prodrug), ranged from 81 to 105 indicatingTable 3 Summary of plasma remogliflozin and GSK279782 PK
Remogliflozin etabonate dose 20 mg 50 mg
Analyte Rb 279782 Rb 27978
AUC(0-∞)
c (ng•h/mL)
Geometric mean (CV%) 133 (45) 51.8 (48) 324 (29) 145 (4
Cmax (ng/mL)
Geometric mean (CV%) 61 (54) 17.5 (72) 158 (44) 50.2 (6
Tmax (h)
Median 0.89 1.26 1.14 1.38
(range) (0.50–1.5) (0.75–2.5) (0.50–1.5) (1.00–2
T½ (h)
Geometric mean (CV%) 1.38 (21) 1.54 (11) 1.47 (15) 2.19 (1
AUC ratio (remogliflozin/
remogliflozin etabonate)
Geometric mean 84d — 81 —
CV% (39) (34)
a. n = 8 unless otherwise specified.
b. R = remogliflozin.
c. The median percentage of AUC(0-∞) extrapolated for R was low ranging from 0.0
d. n = 5.extensive conversion to active entity. The ratios were
consistent across all doses.
An active metabolite of remogliflozin, GSK279782,
was monitored in this study and found to be present in
relatively high concentrations in plasma. An estimated
mean AUC(0-∞) ratio of GSK279782 to remogliflozin
was 40 to 45%. The median Tmax estimates for GSK279782
ranged from 1.0 to 1.5 h and median T½ estimates
ranged from 1.54 to 3.50 h. The concentration profiles
of GSK279782 followed a similar time course to those
of remogliflozin with only a small delay in appearance
of Cmax and slightly longer T½.
The statistical analysis showed AUC(0-∞) and Cmax for
all three analytes increased nearly dose proportionally
over the 50-fold dose range of 20 to 1000 mg in healthyparameters in healthy subjectsa
150 mg 500 mg 1000 mg
2 Rb 279782 Rb 279782 Rb 279782
8) 991 (25) 447 (44) 3721 (29) 1523 (40) 10257 (17) 3995 (22)
2) 515 (37) 155 (50) 1703 (45) 498 (44) 4822 (37) 1286 (28)
0.66 1.00 1.50 1.50 1.25 1.25
.0) (0.33–2.0) (0.75–2.0) (0.50–3.0) (1.00–4.0) (0.50–3.0) (0.75–3.0)
7) 1.59 (13) 2.28(13) 2.57 (29) 3.07 (13) 2.86 (17) 3.50 (12)
102 — 105 — 95 —
(53) (86) (69)
7% to 2.1% across all doses and for 279782 ranging from 0.29% to 4.51%.
Figure 2 Mean plasma concentration-time profiles for remogliflozin etabonate (prodrug), remogliflozin (active entity), and GSK279782
(metabolite) following a 50 mg dose of remogliflozin etabonate to subjects.
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and 90% confidence intervals (CI) for AUC(0-∞) and
Cmax were 1.17 (1.04, 1.30) and 1.04 (0.94, 1.14). For
remogliflozin, the mean slopes and 90% CIs for AUC(0-∞)
and Cmax were 1.09 (1.06, 1.12) and 1.08 (1.02, 1.14). For
GSK279782, the mean slopes and 90% CIs for AUC(0-∞)
and Cmax were 1.08 (1.05, 1.12 and 1.07 (1.01, 1.12).
Type 2 diabetes subjects
The PK parameters for remogliflozin etabonate,
remogliflozin, and GSK279782 in subjects with T2DM
are shown in Table 4. The prodrug was rapidly absorbed
and extensively hydrolyzed to the active entity in patients
as well as non-diabetic subjects. There were no discernableTable 4 Summary of plasma remogliflozin etabonate, remogl
Remog
Remogliflozin etabonate dose 50 m
AUC(0–∞)
c (ng•h/mL)
Geometric mean (CV%) 8.91 (
Cmax (ng/mL)





Geometric mean (CV%) 0.61 (
AUC(0–∞) ratio
(Remogliflozin/remogliflozin etabonate) Geometric mean (CV%) —
a. n = 6 unless otherwise specified.
b. n = 2.
c. The median percentage of AUC(0-∞) extrapolated for remogliflozin etabonate ran
0.42% and for GSK279782 was 0.47% to 2.0%.differences in mean Tmax or T½ values of remogliflozin or
GSK279782 between patients and healthy subjects. The
apparent differences in AUCs for remogliflozin and AUC
ratios between populations are potentially the result of




In both populations, the total amount of glucose excreted
in urine from 0–24 h increased in a dose-dependent
manner; however, urine glucose excretion increased less
than proportionally with increasing doses of remogliflozin
etabonate (Table 5), suggesting a plateau of effect. Theiflozin, and GSK279782 PK parameters in T2DM subjectsa
liflozin etabonate Remogliflozin GSK279782
g 500 mg 50 mg 500 mg 50 mg 500 mg
58) 91.9 (46) b 523 (38) 5176 (44) 130 (50) 1293 (45)
39) 83.9 (89) 195 (46) 1891 (49) 34.6 (39) 314 (39)
8 0.75 1.46 2.50 1.74 2.75
0.78) (0.33–2.50) (0.33–2.00) (0.33–4.00) (0.75–4.00) (0.75–4.00)
32) 0.82 (69) b 1.59 (27) 3.93 (25) 2.05 (24) 3.28 (23)
— 59 (62) 54 (38) — —
ged from 10% to 11% and for remogliflozin was low ranging from 0.14% to
Table 5 24-h urinary glucose and electrolyte excretion, after single-dose administration of remogliflozin etabonate
(20–1000 mg) in healthy volunteers (n = 8 per remogliflozin etabonate group and n = 10 for placebo) and subjects with
T2DM (n = 6)
Parameter Placebo Remogliflozin etabonate dose, mg
20 50 150 500 1000
Healthy subjects
Urinary glucose excretion (mmol) 6.5 (18.6)a 67.1 (17.9) 96.7 (17.1)b 168 (49.4)b 223 (49.5) 304 (137)
Filtered glucose excreted in urine (%) 0.9 (2.4)a 9.0 (2.2) 12.7 (3.7)b 25.5 (7.8)b 34.2 (5.0) 26.4 (11.7)
Urinary sodium excretion (mmol) 162 (49.4)a 148 (64.0) 212 (67.6)b 176 (38.7)b 143 (55.0) 207 (62.9)
Urinary chloride excretion (mmol) 141 (39.8)a 136 (56.6) 189 (51.4)b 179 (49.6)b 126 (55) 201 (61.5)
Urinary potassium excretion (mmol) 62.2 (15.7)a 66.6 (27.7) 75.2 (21.3)b 59.7 (20.3)b 55.8 (17.2) 89.1 (24.7)
T2DM subjects
Urinary glucose excretion (mmol) 40.4 (62.4)c 384 (210) 642 (256)
Filtered glucose excreted in urine (%) 2.3 (3.6)c 15.9 (5.9)c 21.6 (9.1)
Urinary sodium excretion (mmol) 196 (39.2)c 173 (35.5)c 301 (128)
Urinary chloride excretion (mmol) 181 (48.3)c 168 (23.9)c 287 (147)
Urinary potassium excretion (mmol) 71.7 (12.1)c 65.8 (4.5)c 108 (65.8)
Results are expressed as mean (SD).
a. n = 9.
b. n = 7.
c. n = 5.
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http://www.biomedcentral.com/2050-6511/14/1/26urine glucose excretion was higher in the T2DM subjects
due to higher plasma glucose concentrations. When urine
glucose excretion was corrected for circulating plasma
glucose concentrations and CLCR (to provide an estimate
of percentage filtered glucose load or FGL%), the FGL%
was similar between the populations. Figure 3 illustrates
the similarity between populations and the saturation
of urine glucose excretion with increasing doses. The
saturation is related to maximal SGLT2 transporter





























Figure 3 The filtered glucose load (%) vs dose in healthy
volunteers (filled circles) and subjects with T2DM
(open triangles).for the amount of glucose excreted in healthy subjects
over time for each dose.Urine electrolytes
Urine electrolytes are also summarized in Table 5. Urine
excretion of electrolytes was highly variable, and no
treatment-related changes were observed. Much of the
variability in the 500 mg dose period can be attributed
to one subject (#12) whose values for all three electrolytes
were roughly 2-fold higher than those of the other









































Figure 4 Mean cumulative 24-h urine glucose excretion
following single-dose administration of remogliflozin











































Placebo     50 mg     500 mg
Figure 5 Plasma glucose and insulin AUC0-4 h following glucose challenge in subjects with T2DM.
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For healthy subjects, AUC values for plasma glucose
were very similar between placebo and remogliflozin
etabonate periods at both 0–4 h (mean of approximately
18 mmol•h/L) and 0–12 h (mean of approximately
55–59 mmol•h/L) following study drug administration.
For T2DM subjects, the increases in plasma glucose
following an OGTT were clearly attenuated between
placebo and 50 mg RE; the effect on glucose was altered
little by increasing the dose from 50 mg to 500 mg RE.
There were no clear trends in plasma insulin following
the glucose load. The baseline adjusted AUC(0–4) values
for plasma glucose and insulin following an OGTT, are
depicted in Figure 5.
Plasma intact GLP-1
In T2DM subjects, the median baseline adjusted AUC(0–4)
for plasma GLP-1 following an OGTT was 6.36 pM*h
(range, 0 to 16.6) for placebo, -8.85 pM*h (range, -46.7 to
33.4) for remogliflozin etabonate 50 mg, and -1.95 pM*h
(range, -11.6 to 7.0) for remogliflozin etabonate 500 mg.
These data are difficult to interpret because the ranges
for placebo, 50 mg, and 500 mg groups contain zero,Table 6 Summary of fluid balance data (mL)
Placebo 20 mg 5
Healthy Subjects (n = 10) (n = 8) (n
−24 h to pre-dose −462 (605) −460 (1311) −33
0–12 h post-dose 163 (668) 243 (1161) −57
12–24 h post-dose −739 (423) −581 (387) −55
T2DM subjects n = 6 n
−24 h to pre-dose −312 (457) −50
0–12 h post-dose 569 (400) −7
12–24 h post-dose −908 (524) −80
Fluid balance = total fluid intake minus total urine volume.
Results are expressed as mean (SD).and also because the analytical method likely did not
include extraction of the samples, which can confound
the analysis of intact GLP-1 [24,25].
Fluid balance
Fluid balance data for both healthy and T2DM subjects
are shown in Table 6.
On the day prior to dosing in healthy subjects, fluid
balance (total fluid intake minus total urine volume) was
negative (mean volumes in the range of -126 to -512 mL).
In the 0–12 h interval after dosing, fluid balance shifted to
positive for the placebo (+163 mL) and 20 mg remogliflozin
etabonate (+242 mL) periods, while the 50 to 1000 mg
remogliflozin etabonate treatment periods remained
negative. For the 12 to 24 h post-dose interval, all regimens
had a fluid balance that was negative. There was no
evidence of a clear dose–response.
In T2DM subjects, fluid balance was variable in the
24 h prior to dosing; T2DM subjects assigned to placebo
and remogliflozin etabonate 50 mg had a negative fluid
balance (mean volumes ranging from -312 mL to -504 mL),
while those assigned to remogliflozin etabonate 500 mg
had a positive fluid balance (mean volume +188 mL). FromRemogliflozin etabonate dose
0 mg 150 mg 500 mg 1000 mg
= 8) (n = 8) (n = 8) (n = 8)
8 (525) −512 (731) −278 (1250) −126 (798)
0 (582) −86 (909) −159 (531) −273 (331)
1 (530) −564 (478) −424 (334) −495(367)
= 6 n = 6
4 (294) 188 (1879)
8(433) −29 (749)
3 (658) −1088(679)
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cebo regimen and negative for the remogliflozin etabonate
50 mg and 500 mg regimens. For the 12–24 h interval, all
regimens had negative fluid balance (mean volumes ranging
from -802 mL to -1087 mL). As with the healthy subjects,
there was no clear dose–response.
Discussion
By promoting urinary glucose excretion, SGLT2 inhibitors
offer a novel mechanism of antidiabetic action that is
complementary to currently available classes of drugs
which reduce hepatic gluconeogenesis (e.g. metformin),
increase glucose flux into muscle and fat (e.g. insulin sensi-
tizers such as thiazolidinediones) or stimulate β-cell insulin
secretion (e.g. GLP-1-based therapies).
In both healthy and T2DM subject populations, the
prodrug, remogliflozin etabonate was extensively
converted to its active entity, remogliflozin, and to an
active metabolite, GSK279782, which is as potent as
remogliflozin in inhibiting SGLT-2 in vitro [23]. The
PK parameters (Cmax and AUC) of all three analytes
(remogliflozin etabonate, remogliflozin, and GSK279782)
increased nearly dose proportionally over the 50-fold dose
range, 20 to 1000 mg, of remogliflozin etabonate in
healthy subjects. Although limited data are available, there
appeared to be dose proportionality in subjects with
T2DM between 50 and 500 mg doses as well. The PK pa-
rameters were similar between the healthy subjects and
T2DM subjects.
Evidence of the desired pharmacological effect was
seen in the dose-dependent increase in urinary glucose
excretion in healthy subjects and in T2DM subjects follow-
ing administration of remogliflozin etabonate. The total
amount of glucose excreted in the 24 h after dosing
increased less than proportional to the dose and exposure
to remogliflozin in healthy subjects. The plateau in glucose
excretion was observed between exposures associated with
single doses of 150 mg and 500 mg, suggesting maximal
inhibition of the SGLT2 transporter at this dose range. Sub-
jects with T2DM showed increased glucose excretion over
24 hours with increasing doses of remogliflozin etabonate,
but the percentage of filtered glucose excreted was similar
between the two study groups. This amount of urine
glucose excretion has been predicted to provide clinically
meaningful reduction in plasma glucose [26]. For subjects
withT2DM, the increase in plasma glucose following an oral
glucose load appeared to be blunted in a drug-dependent
fashion following dosing with remogliflozin etabonate,
suggesting that SGLT2 inhibition is an appropriate mech-
anism for glucose lowering in these patients.
Conclusions
This single-dose evaluation is the first clinical study to be
conducted with remogliflozin etabonate, and it providessafety, tolerability, pharmacokinetic and pharmacodynamic
information in both healthy subjects and those with
T2DM. In this study, single oral doses of remogliflozin
etabonate (20 mg to 1000 mg for healthy subjects; 50 mg
and 500 mg for subjects with T2DM) were generally safe
and well-tolerated. Clinically significant fluid and electrolyte
imbalances were not seen in this study, but longer repeat
dose studies will be required to establish the safety profile.
Remogliflozin etabonate increased urinary glucose excre-
tion in a dose dependent fashion and also blunted increases
in plasma glucose following an oral glucose load, which
suggests that remogliflozin etabonate could be useful as a
treatment for T2DM.
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